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slowly passing dropwise either the chitosan 0.6%-alginate 1.2% or the alginate
1.2% solution through a syringe into a 102 mM CaCl2 solution. Beads were
analyzed histologically after 28 days. Interleukin (IL)-6 and -8, prostaglandin (PG)
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were quantified directly in the culture supernatant by specific ELISA and nitric
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Hematoxylin and eosin staining showed that chitosan was homogeneously
distributed through the matrix and was in direct contact with chondrocytes. The
production of IL-6, IL-8 and MMP-3 by chondrocytes significantly decreased in
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Abstract
This in vitro study investigated the metabolism of human osteoarthritic (OA) chondrocytes
encapsulated in a spherical matrix enriched of chitosan. Human OA chondrocytes were en-
capsulated and cultured for 28 days either in chitosan-alginate beads or in alginate beads.
The beads were formed by slowly passing dropwise either the chitosan 0.6%–alginate 1.2%
or the alginate 1.2% solution through a syringe into a 102 mM CaCl2 solution. Beads were
analyzed histologically after 28 days. Interleukin (IL)-6 and -8, prostaglandin (PG) E2, matrix
metalloproteinases (MMPs), hyaluronan and aggrecan were quantified directly in the cul-
ture supernatant by specific ELISA and nitric oxide (NO) by using a colorimetric method
based on the Griess reaction. Hematoxylin and eosin staining showed that chitosan was ho-
mogeneously distributed through the matrix and was in direct contact with chondrocytes.
The production of IL-6, IL-8 and MMP-3 by chondrocytes significantly decreased in chito-
san-alginate beads compared to alginate beads. PGE2 and NO decreased also significantly
but only during the first three days of culture. Hyaluronan and aggrecan production tended
to increase in chitosan-alginate beads after 28 days of culture. Chitosan-alginate beads re-
duced the production of inflammatory and catabolic mediators by OA chondrocytes and
tended to stimulate the synthesis of cartilage matrix components. These particular effects
indicate that chitosan-alginate beads are an interesting scaffold for chondrocytes encapsu-
lation before transplantation to repair cartilage defects.
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Introduction
Osteoarthritis (OA) is a degenerative disease associated with many structural and functional
disorders leading to the loss of joint integrity and function. It is the most prevalent form of ar-
thritic disease in the world. It is mainly characterized by the slow progressive degeneration and
the loss of articular cartilage accompanied by modification of the subchondral bone and syno-
vial membrane inflammation [1]. In cartilage, an imbalance between anabolic and catabolic
processes occurs and results in the progressive degradation of the extracellular matrix [2]. The
catabolic response is induced by pro-inflammatory mediators (e.g. interleukin (IL)-1, IL-8, IL-
6) and characterized by the overexpression of metalloproteinases (MMPs) including collage-
nases, stromelysin and tissue plasminogen activator, and by the production of prostaglandin
(PG) E2 and nitric oxide (NO) [3].
Since no cure has been discovered so far for OA, the management of OA is focused on the
control of symptoms, i.e. pain and loss of articular function. The guidelines recommend a com-
bination of non-pharmacological (i.e. exercises, orthoses, insoles, weight loss) and pharmaco-
logical modalities (e.g. NSAIDS, paracetamol) as the most effective strategy to manage pain
and disability associated with OA [4–10]. An alternative approach is the use of topical NSAIDs
and intra-articular therapy such hyaluronic acid or glucocorticoids injection. Surgery, includ-
ing arthroplasty, is recommended only as a last resort [5, 11].
Aside these treatments, debridement [12], chondral shaving, knee joint lavage can also be
performed by a minimally invasive arthroscopic procedure. The purpose of these interventions
is to reduce the pain and to improve the mobility. However, they are not able to restore carti-
lage [13, 14]. Microfracture, subchondral drilling, osteochondral allograft and autologous
chondrocytes implantation assisted or not with matrix are current perspectives under investi-
gation [15–17].
One promising approach to repair cartilage is the transplantation of autologous chondro-
cytes or stem cells into cartilage defect using natural or synthetic scaffold [18]. To perform this
function, the scaffold must be biocompatible with the cartilaginous tissue, biodegradable, non-
toxic and non-immunogenic [19]. Natural biopolymers such as alginate [20–23] and chitosan
[24–27] are among the most investigated biomaterials for cartilage regeneration [28].
Chitosan is a linear natural polymer of D-glucosamine with a variable frequency of N-ace-
tyl-D-glucosamine units that is the product obtained after chemical N-deacetylation treatment
of chitin [29] which is the most abundant natural polymer after cellulose. It is present in the
cell wall of fungi and the exoskeleton of shellfishes and insects. Chitosan is a fascinating candi-
date for biomedical applications such as biomaterials for tissue-engineered scaffold and tissue
repair. Indeed, it has relevant biological proprieties such as biocompatibility, progressive de-
gradability, absence of toxicity, lack of allergenicity and antibacterial activity [30]. Moreover, in
vitro studies have showed that chitosan or modified chitosan promoted the expression of carti-
lage matrix compounds by chondrocytes [31–33]. These studies suggested that chitosan could
be a good biomaterial for cartilage tissue engineering.
The aim of this work was to prepare a biocompatible three-dimensional biomaterial by mix-
ing chitosan and alginate, and to investigate in vitro the biological behavior of human OA artic-
ular chondrocytes embedded in this biomaterial.
Materials and Methods
Specimen selection
Human cartilage was obtained from knee joints of 16 different OA patients, after total knee re-
placement surgery with a mean ± SEM age of 72.53 ± 7.09 and ranged between 61–83 years.
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Upon dissection, the femoral, tibial and patellar articular surfaces were evaluated for the patho-
logical cartilage modifications according to the Moskowitz scale [34]. All cartilage samples
showed typical OA lesions. The tissues used in this study were obtained after patient informed
consent. The project was discussed with the patient verbally by the orthopedic surgeon and if
the patient agreed to participate written consent was then taken. This consent procedure and
the study were approved by Ethics Committee Approval of the University of Louvain (refer-
ence number B403201214793).
Isolation of human OA chondrocytes
Cartilage was cut into small fragments and submitted to sequential enzymatic digestion with
hyaluronidase, pronase and collagenase, as previously described [35]. The cells were then fil-
tered through a nylon mesh with a pore diameter of 70 μm, and washed 2 times with 0.9%
NaCl. Cell viability was estimated by trypan blue exclusion test. The chondrocytes were then
pooled and used into four independent cultures (n = 4).
Preparation of alginate and chitosan-alginate beads
The alginate beads were performed by suspending chondrocytes in 1.2% (w/v) low viscosity al-
ginate (Sigma-Aldrich, Bornem, Belgium) solution at a density of 6 x 106 cells/mL as previously
described by Sanchez et al. [36].
To prepare chitosan-alginate (CA) beads, 1.33% (w/v) chitosan solution and 2.4% (w/v) al-
ginate solutions were prepared separately by dissolving 1 g of ultrapure medical-grade vegeta-
ble chitosan (KiOmedine-CsU from KitoZyme, Herstal, Belgium) in 75 mL 0.166 M acetic acid
and 2 g low viscosity alginate in 83.3 mL 0.16 M NaOH. The solutions were then mixed to ob-
tain a solution containing 0.6% (w/v) chitosan and 1.2% (w/v) alginate. Chondrocytes were
suspended in the chitosan-alginate solution at the density of 6 x 106 cells/mL. This mixture was
slowly passed dropwise through a syringe into a 102 mM CaCl2 solution (Sigma). After instan-
taneous gelation the beads were incubated for 10 min in the CaCl2 solution and washed with
saline solution. The chitosan used to prepare the beads had a molecular weight of 30,700 Da
and 15.7 mol % of degree of acetylation. To visualize the chitosan distribution, some beads
were prepared using similar chitosan labeled with fluorescein isothiocyanate (chitosan-FITC;
generously provided by KitoZyme). The viscosity of chitosan-alginate solution was 294 cP
(measured at 25°C with a Brookfield LVDV-II+PRO viscosimeter using a spindle 18 (Brook-
field Engineering Laboratories, Middleboro, Massachusetts, USA)). The osmolarity of the chit-
osan-alginate solution was 256.33 ± 1.53 (mean ± SEM) mOsmol/kg using the Osmometer
automatic type 15 (LÖSER; Ficsher Scientist, Aalst, Belgium). The pH, measured at 19°C with
Microprocessor pH-mVMeter pH 526 (VWR, Leuven, Belgium) of chitosan-alginate solutions
was 7.35 ± 0.05 (mean ± SEM). The preparation of CA beads was performed by passing drop-
lets thought a syringe with a 25 G needle. This method produced spherical beads (Fig 1A) with
a mean ± SEM diameter (measured with a digital Vernier caliper) of 2.17 ± 0.23 mm.
Chondrocytes culture in A or CA beads
Nine beads were placed in each well of a 24 wells plate and cultured in 1 ml of DMEM (Lonza,
Verviers, Belgium) supplemented with 10% foetal calf serum (Lonza), 10 mMHEPES (Lonza),
100 U/mL penicillin (Lonza), 100 μg/mL streptomycin (Lonza), 2 mM L-glutamine (Lonza),
50 μg/mL ascorbic acid (Sigma), 20 μg/mL proline (Sigma) at 37°C with 5% CO2 in a humidi-
fied atmosphere. The culture medium was changed twice a week and the collected supernatants
were kept at -20°C until analysis. Beads were maintained in culture for up to 28 days.
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Beads and supernatants were collected after key intervals throughout the culture period (i.e.
0–3, 17–21, 24–28 days). The beads were then dissolved in 1 mL 0.1 M citrate solution. The
suspension was centrifuged (Centrifuge 5810, Eppendorf; VWR, Leuven, Belgium) at 300 g for
10 min. With this method, two fractions were collected: the supernatant containing macromol-
ecules from the further-removed matrix (FRM) and a pellet containing cells with their associat-
ed cellular matrix (CM) [37]. These two fractions were studied separately. The cell pellets were
washed with phosphate buffered saline (PBS; Lonza), homogenized in 1 mL Tris buffer (10
mM Tris, 50 mM KCl, pH 9) by ultrasonic dissociation at 4°C and then centrifuged at 150 g for
10 min. CM and FRM were kept at -20°C until analysis.
Scanning electron microscopy observation
Chitosan-alginate beads were observed both in an environmental scanning electron micro-
scope (ESEM) in low vacuum "wet" mode and in a classical scanning electron microscope
(SEM) under high vacuum conditions. For environmental SEM, the wet beads were directly
placed on steel stub cooled at 2°C by a "Peltier" unit in the chamber of a FEI ESEM-FEG XL-30.
The observation pressure started at 7 Torr and was progressively decreased to 2 Torr leading to
the slow dehydration of the sample. The images were obtained using a gaseous secondary elec-
tron detector (GSED-Electroscan) with a 500 μm pressure limiting aperture (PLA) and under
12 to 20kV accelerating voltages. For classical SEM, the chitosan-alginate beads were first dehy-
drated in ethanol then critical point dried in CO2. After mounting on an aluminum stub, they
Fig 1. Macroscopic and electron microscopic appearance of chitosan-alginate beads.Macroscopic image of chitosan-alginate beads (A). Scanning
electron micrograph of chitosan-alginate bead (B; original magnification x50) showing the surface morphology (C; original magnification x2000), the internal
morphology (D; original magnification x5000) and the alginate matrix (E; original magnification x10000).
doi:10.1371/journal.pone.0128362.g001
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were platinum-coated (20 nm) in a Balzers SCD-030 sputtering unit. Some of them were teared
to visualize their internal structure. The observations were realized in a SEM Jeol JSM-840A
(Jeol, Zaventem, Belgium) under a 22kV accelerating voltage.
TEM observation was also realized on CA bead containing chondrocytes after 28 days of
culture. Beads were fixed for 2 h at 4°C in 2.5% glutaraldelyde in 0.1 M sodium cacodylate (pH
7.4) and then for 1 h at 4°C in 1% osmium tetroxide in 0.1 M sodium cacodylate, pH 7.4. Sam-
ples were then dehydrated with increasing concentrations of ethanol and propylene oxide and
embedded in LX112 resin (LADD, Williston, Vermont, USA) before polymerization at increas-
ing temperatures (37°C for 24 h; 47°C for 24 h; 60°C for 48 h). For orientation purpose, 2 μm
sections were performed, stained with toluidine blue, and observed by light microscopy. Ultra-
thin sections (50–70 nm) were cut, stained with uranyl acetate, contrasted with lead citrate,
mounted on uncoated grids, and observed by TEM (FEI Tecnai G2TWIN, 200kV, Eindhoven,
The Netherlands).
Histological analysis of beads
At the end of 28 days of culture, beads were fixed with 4% paraformaldehyde in 100 mM sodi-
um-cacodylate buffer, pH 7.4, for 4 h at 4°C; 20 mM CaCl2 was added to prevent disintegration
of the beads. After washing overnight at 4°C in 100 mM sodium-cacodylate buffer, the beads
were dehydrated in graded series of methanol, placed in a xylene wash before being embedded
in paraffin. Five μm sections were cut with a microtome (Leica RM 2145; Leica, Diegem, Bel-
gium) rehydrated and stained with hematoxylin-eosin, alcian blue or safranin-O/fast green. To
visualize chitosan-FITC, hematoxylin-eosin stained sections of beads were observed using H3
filtercube (Leica). Alcian blue and safranin-O/fast green staining methods were used to analyze
cartilage tissue formation. For safranin-O/fast green staining, sections were counterstained
with hematoxylin (Merck, Darmstadt, Germany) and fast green (Merck) to visualize cells and
cell nuclei, respectively. Safranin-O (Sigma) was used for visualization of glycosaminoglycans
(GAGs) in red. Sections were also stained with alcian blue solution (1% in acetic acid) to visual-
ize extracellular GAGs in blue.
DNA and total protein assay
The DNA content was measured in the CM fraction using the fluorimetric method with Pico-
Green dsDNA reagent (Quant-iT PicoGreen dsDNA; Life Technologies, Gent, Belgium). Total
protein was also quantified in the CM fraction utilizing bicinchoninic acid (BCA) as the detec-
tion reagent for Cu+1, which is formed when Cu+2 is reduced by protein in alkaline environ-
ment (Micro BCA Protein Assay Kit, Rockford, USA). Results were expressed in μg/mL after
3 days, 21 days and 28 days of culture in text.
Immunoassays for hyaluronan, aggrecan, IL-6, IL-8, PGE2 and MMPs
Hyaluronan (DuoSet ELISA, R&D, Abingdon, UK), IL-6, IL-8, aggrecan, MMP-3 (Enzyme
Amplified Sensitivity Immunoassays; Biosource Europe, Merelbeke, Belgium), PGE2 (DetectX
Prostaglandin E2 High Sensitivity immunoassay; Arbor, Michigan, USA) and MMP-1; -2; -9;
-13 (Fluorokine MAP, R&D) were measured in different compartments (culture supernatant,
FRM and CM) after key intervals throughout the culture time (i.e. 0–3, 17–21, 24–28 days) ac-
cording to the manufacturer’s recommendations. No cross-reactivity existed between IL-6 and
IL-8 assays. Less than 0.5% cross-reactivity and interference was observed between MMPs. The
production of hyaluronan and aggrecan were expressed in ng/μg of DNA in text and, respec-
tively, in figure and in table after 3 days, 21 days and 28 days of culture. The production of IL-
6, IL-8, and PGE2 were expressed in pg/μg of DNA and MMP-3 in ng/μg of DNA after 0–3,
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17–21, 24–28 days of culture in table. Results of IL-6, IL-8, PGE2 and MMP-3 were also ex-
pressed in percentage of production in comparison with alginate considered as control (100%)
in table.
Nitrite assay
The spectrophotometric method based upon the Griess reaction was used to quantify nitrite in
different compartments after key intervals throughout the culture time (i.e. 0–3, 17–21, 24–28
days). Griess reagent (0.5% sulphanilamide, 0.05% naphtyl ethylenediamine dihydrochloride,
2.5% H3PO4) was mixed with 100 μL of conditioned culture medium or sodium nitrite
(NaNO2, standard solution). The absorption was measured at 540 nm. The NO production
was expressed in nmol/μg of DNA in text.
Statistical analysis
The results are presented as mean (95% confidence interval). Experiments were performed in
triplicate and the obtained values were average for the purpose of statistical analysis. Statistical
significance was determined using GraphPad Prism software, version 6 for DNA, total protein,
hyaluronan, aggrecan, IL-6, IL-8, PGE2, and MMPs after one way ANOVA, followed, if posi-
tive by the Bonferroni’s multiple comparison post-test and for NO, after Student’s t-test. P-val-
ues were considered significant when p<0.05.
Results
SEM analysis of the CA beads
Two different techniques, SEM and ESEM, have been performed to observe the ultrastructure
of the beads. Classical SEM pictures were the most relevant for illustrating the aspect of the CA
beads (Fig 1B–1E). The surface showed microreliefs visible at high magnification (x2000; Fig
1C). The visualization of the internal structure by tearing bead revealed large filaments (about
10 μm thick) with a smooth folded surface, the chitosan trabeculae (Fig 1D), surrounded by a
microporous network of thin interconnected filaments (less than 100 nm in thickness) visible
at a high magnification (x10000) probably corresponding to the alginate matrix (Fig 1E).
TEM observation of chondrocytes embedded in CA beads
Chondrocytes cultivated in CA beads during 28 days were observed by TEM (Fig 2A–2D). CA
beads sections showed mostly single chondrocytes although sometimes small clusters, contain-
ing about 3–5 cells, were seen as well dispersed among chitosan trabeculae. A spherical mor-
phology of chondrocyte about 10 μm in diameter with typical matrix organization (Fig 2A–2C)
was observed. Pericellular matrix characterized by microvillus with matrix vesicles (Fig 2B)
was followed by a fine granules appearance that corresponded to territorial matrix and extra-
cellular matrix. Fig 2C and 2D showed an electron dense flaky accumulation around chondro-
cytes. An enlargement of an area (Fig 2D) revealed a direct contact between territorial matrix
and likely chitosan.
Histological analysis of the beads
To identify chitosan trabeculae, we have labeled chitosan with FITC (Fig 3A). Fig 3B showed
that chitosan trabeculae were homogenously distributed in the bead. Hematoxylin-eosin stain-
ing revealed that the chondrocytes cultivated for 28 days in A (Fig 3C) or CA (Fig 3D) beads
were spherical, located in lacuna, scattered in matrix and isolated from each other as in native
articular cartilage. Direct contact between chondrocytes and chitosan trabeculae was observed
Chondrocytes in Chitosan Beads
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(Fig 3D). Safranin-O (Fig 4A and 4B) and alcian blue (Fig 4C and 4D) both stained GAGs.
After 28 days of culture, a higher amount of GAGs accumulated around chondrocytes in CA
beads compared to A beads as revealed by the red staining in Safranin-O (Fig 4B) and the blue
staining in alcian blue (Fig 4D).
DNA and total protein quantification
In CA beads, DNA content in CM fraction remained constant over time (3 days: 5.1 (2.4–7.9)
μg/mL vs 21 days: 5.2 (3.2–7.2) μg/mL vs 28 days: 5.4 (3.1–7.6) μg/mL). In contrast, DNA con-
tent tended to increase after 21 and 28 days of culture in A beads (p>0.05; 3 days: 4.7 (1.9–7.4)
μg/mL vs 21 days: 6.7 (3.3–10.1) μg/mL vs 28 days: 7.1 (4.1–10.1) μg/mL) days in comparison
Fig 2. Transmission electronmicroscopy of chondrocytes in chitosan-alginate beads sections. Transmission electron micrograph of chondrocytes
(A-D). N = nucleus. Δ represented pericellular matrix. TM = territorial matrix. ECM = extracellular matrix. Areas surrounded in (B) presented matrix‘s
microvillus. Arrow in (C-D) represented flaky accumulation around chondrocyte.
doi:10.1371/journal.pone.0128362.g002
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to 3 days. Total protein content in A or CA beads did not change with time (p>0.05; A beads:
3 days: 125.3 (98.3–152.2) μg/mL vs 21 days: 164.3 (136.2–192.3) μg/mL vs 28 days: 166.7
(134.4–199.0) μg/mL; CA beads: 3 days: 127.5 (103.2–151.8) μg/mL vs 21 days: 129.6 (106.7–
152.6) μg/mL vs 28 days: 141.6 (106.2–177.0) μg/mL).
Fig 3. Hematoxylin and eosin stained section from alginate and chitosan-alginate beads. Fluorescence microscopy in chitosan-alginate beads section
(A). The same section stained by hematoxylin and eosin (B; original magnification x20). Section in alginate (C) or chitosan-alginate (D) beads stained by
hematoxylin and eosin (original magnification x40). Black triangles represented chitosan trabeculae, black diamonds represented chondrocytes and
"showed contact.
doi:10.1371/journal.pone.0128362.g003
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Production of hyaluronan and aggrecan compound
Hyaluronan and aggrecan production was measured in culture supernatant, FRM and CM
fractions. Hyaluronan was detected in these three fractions (Fig 5). No significant difference
was observed after 3 and 21 days of culture between A (p>0.05; 3 days: 197 (97–297) ng/μg
DNA vs 21 days: 142 (94–190) ng/μg DNA) and CA (3 days: 194 (75–313) ng/μg DNA vs 21
Fig 4. Safranin-O/fast green and alcian blue stained sections from alginate and chitosan-alginate beads. Sections in alginate (A and C) or chitosan-
alginate (B and D) beads. Safranin-O/fast green (A and B) or alcian blue staining (C and D). Original magnification x20. Black triangles represented chitosan
trabeculae, black diamonds represented chondrocytes and stars indicated GAGs deposition.
doi:10.1371/journal.pone.0128362.g004
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days: 137 (92–183) ng/μg DNA) beads. However, hyaluronan tended to increase in CA beads
(165 (126–205) ng/μg DNA) in comparison to A beads (139 (118–160) ng/μg DNA; p>0.05)
after 28 days of culture (Fig 5). No aggrecan was detected in culture supernatant (data not
shown). Nevertheless, aggrecan was detected in both FRM and CM fractions after 3, 21 and 28
days of culture. As reported in Table 1, aggrecan accumulated in the extracellular matrix in
both A and CA beads. After 21 days of culture, aggrecan accumulated in the beads was 1.2 fold
greater in CA beads compared to A beads (p>0.05) In contrast, no trends were observed after
3 and 28 days (Table 1).
Production of inflammation mediators
Inflammatory mediators were quantified in all compartments but only detectable in the culture
supernatants (data not shown). In comparison with A beads, CA beads significantly reduced
the production of IL-6 (p = 0.0012), IL-8 (p<0.0001) and PGE2 (p = 0.0056) after 3 days of
Fig 5. Production of hyaluronan by chondrocytes in alginate and chitosan-alginate beads.Hyaluronan was quantified in CM (cellular matrix), FRM
(further-removed matrix) and culture supernatant after key intervals throughout the culture time (i.e. 3, 21, 28 days). Productions were expressed in absolute
values (ng) and normalized to DNA content. Results were presented as mean ± SEM of 4 independent experiments (n = 4). Statistical significance was
determined after one way ANOVA, followed, if positive, by the Bonferroni’s multiple comparison post-test.
doi:10.1371/journal.pone.0128362.g005
Table 1. Production of aggrecan (ng/μg DNA) by chondrocytes in A and CA beads after key intervals
throughout the culture time: 3, 21, 28 days.
Beads Days FRM CM FRM+CM
A 3 615 (604–1,835) 377 (182–936) 992 (778–2,764)
21 1,490 (900–2,080) 578 (190–966) 2,068 (1,243–2,892)
28 2,179 (497–4,856) 520 (103–936) 2,699 (333–5,732)
CA 3 481 (332–1,294) 272 (90–635) 753 (469–1,925)
21 2,036 (381–3,691) 446 (283–609) 2,482 (741–4,223)
28 2,177 (30–4,384) 387 (271–502) 2,564 (362–4,765)
Values are reported as mean (95% conﬁdence interval) FRM: Further-removed matrix; CM: Cellular matrix;
A: alginate; CA: chitosan-alginate
doi:10.1371/journal.pone.0128362.t001
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culture (Table 2). This significant inhibitory effect was sustained during the culture period of
17–21 days for both IL-6 (p = 0.0028) and IL-8 (p<0.0001) and during the culture period 24–
28 days for IL-8 (p<0.0001). Moreover, after 3 days of culture, NO production decreased sig-
nificantly (p = 0.0010) in CA (2.9 (0.2–5.6) nmol/μg DNA) beads compared to A beads (9.5
(4.1–22.4) nmol/μg DNA). No detectable levels of NO were found in culture supernatants after
3 days of culture (data not shown).
MMPs production
MMP-1, -2, -9, -13 productions were not significantly modified by matrix composition and by
culture times (data not show). In comparison to A beads, the production of MMP-3 was signif-
icantly decreased in CA beads (Table 2) after 3 days of culture (p = 0.0025) and during the 17–
21 days of culture period (p = 0.0043). During the period of 24–28 days, the production of
MMP-3 in CA beads was lower than the in A beads but the difference was not significant
(p>0.05).
Discussion
This work describes an original method to incorporate cells in chitosan enriched matrix and
the influence of this tridimensional matrix on chondrocytes metabolism. This patented method
[38] consists of a mixing procedure of alginate alkaline and chitosan acid solution, the gelation
of this mixture, and the incorporation of cells in a neutral solution that was suitable to culture.
Patent can be found in S1 File.
In this new biomaterial chondrocytes were like in cartilage matrix: scattered, isolated from
each other, spherical and surrounded by typical organization zones of the matrix. Moreover,
microscopic analysis has revealed that chondrocytes were in contact with chitosan trabeculae
especially with territorial matrix. This fact possibly explained the particular behavior of
Table 2. Production of IL-6, IL-8, PGE2 and MMP-3 by chondrocytes in A and CA beads after key intervals throughout the culture time: 0–3, 17–21,
24–28 days.
0–3 17–21 24–28
IL-6 A (pg/μg DNA) 8,153 (4,286–20,592) 695 (95–1,484) 229 (1–460)
CA (pg/μg DNA) 2,530 (1,689–6,750) 229 (114–573) 147 (99–395)
% of alginate control 22 (1–43) ** 28 (5–63) ** 78 (13–169)
IL-8 A (pg/μg DNA) 30,286 (13,757–74,328) 2,404 (116–4,691) 501 (156–845)
CA (pg/μg DNA) 11,773 (10,964–34,509) 197 (68–463) 108 (18–235)
% of alginate control 39 (4–74) *** 8 (3–19) *** 21 (2–43) ***
PGE2 A (pg/μg DNA) 10,894 (411–22,199) 354 (331–1,040) 105 (7–217)
CA (pg/μg DNA) 3,153 (261–6,568) 320 (229–869) 84 (32–201)
% of alginate control 31 (21–41) ** 102 (9–195) 82 (36–129)
MMP-3 A (ng/μg DNA) 3,984 (5,002–12,970) 1,727 (1,686–5,140) 460 (109–810)
CA (ng/μg DNA) 2,328 (3,523–8,179) 498 (59–1,056) 335 (65–605)
% of alginate control 46 (29–64) ** 50 (19–119) ** 73 (53–92)
Production of IL-6, IL-8 PGE2 and MMP-3 by chondrocytes in A and CA beads. IL-6, IL-8, PGE2and MMP-3 were quantiﬁed in cell culture supernatants
after key intervals throughout the culture time (i.e. 0–3, 17–21, 24–28 days). Productions were normalized to DNA content. Results were expressed as
concentration per μg DNA of chondrocyte production in A and CA beads, and as the percentage of chondrocyte production in A beads (100% = control).
Results were expressed as mean (95% conﬁdence interval) of 4 independent experiments (n = 4). Statistical signiﬁcance in comparison to production in A
beads (100% = control) was determined after one way ANOVA, followed, if positive, by the Bonferroni’s multiple comparison post-test: A vs CA:
*** p<0.001; ** p<0.01.
doi:10.1371/journal.pone.0128362.t002
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chondrocytes when they are cultured in this biomaterial. Using FITC-labeled chitosan and
electronic microscopy, we have observed that chitosan trabeculae formed a network filled by al-
ginate fibers. Taken all together, these results showed that CA beads were an original and inter-
esting biomaterial. Indeed, all methods used so far did not allowed alginate, chitosan and cell to
mix. An alginate scaffold surrounded by a shell of chitosan [39, 40] has been developed. In that
biomaterial, chitosan and alginate formed two separate phases. Cells were resuspended in algi-
nate solution with no contact between chitosan and cells. Another production method for algi-
nate-chitosan mixed scaffold [41–43] required freezing and freeze drying step that were not
relevant and suitable technical procedures for embedded cell culture. Another, particularity of
this biomaterial was the non-animal origin of the chitosan. We have used an ultra-pure chito-
san extracted from Agaricus bisporusmushroom.
This study also demonstrated that the presence of chitosan in the extracellular matrix affect-
ed beneficially human chondrocytes metabolism. In summary, chondrocytes cultured in CA
beads produced more GAGs but less pro-inflammatory mediators and catabolic factors. Clear-
ly, these findings indicated that chitosan may exert a positive influence on chondrocyte and
promote matrix deposition. Indeed, the presence of chitosan promoted the accumulation of
GAGs around the cells revealed by blue alcian and safranin O/fast green staining. In addition,
using an immunoassay specific for the aggrecan, we have shown that aggrecan contained in the
surrounding matrix was higher in CA beads suggesting that CA matrix may accelerate aggre-
can deposition in the extracellular matrix. These results confirmed a previous work demon-
strating that aggrecan gene expression by chondrocytes cultivated on a pre-coated 4% chitosan
coverchip for 7 days was higher than on uncoated coverslips [31]. In contrast, hyaluronan con-
tent remained stable whatever the culture condition. Another key result of our study was the
fast inhibitory effect of chitosan matrix on the production of inflammatory mediators and cata-
bolic factors. These results are very important in the context of the treatment of OA cartilage
defect. Indeed, in vitro and in vivo studies have shown the major role played by IL-6, IL-8, NO
and PGE2 in cartilage degradation [44–47] and synovitis onset and progression [48, 49]. In
fact, an excessive production of cytokines by the inflamed synovium and activated chondro-
cytes play an important role in the pathophysiology of OA. IL-1β and TNFα can stimulate
their own production and induce chondrocytes and synovial cells to produce other cytokines,
such as IL-8, IL-6 and PGE2 production [47]. NO is also a factor involved in the IL-1β-mediat-
ed catabolic effect and then also participate to cartilage metabolism dysregulation [50]. These
data corroborate those of previous studies reporting an anti-inflammatory action of chitosan.
Pangestuti et al. demonstrated that chitosan at the concentration of 500 μg/mL in solution in-
hibited PGE2, NO and IL-6 production by murine BV2 microglia cells [51]. Another interest-
ing study [52] showed that chitosan oligosaccharide pretreatment inhibited NO production by
HT-29 cells.
An important decrease of MMP-3 production was also observed in the CA beads compared
to A beads suggesting an anti-catabolic effect of chitosan. Indeed, MMP-3 was shown to be re-
sponsible for the proteolysis of extracellular matrix proteins, mainly aggrecan [53] and of the
activation of pro-collagenases [54, 55]. By this way, MMP-3 participates in metalloproteinase
cascade activation and in consequence to cartilage degradation [56, 57]. These results are in ac-
cordance with those of Liu et al. [58] showing that 2% of carboxymethylated chitosan solution
injected in rabbit knee significantly decreased MMP-3 mRNA cartilage expression 6 weeks
after injection. More surprising was the absence of CA effects on the other MMPs. This could
be explained by a specific binding between chitosan matrix and MMP-3 limiting MMP-3 re-
lease in the culture supernatant or by a specific action of CA matrix on MMP-3 signaling path-
way. However, these hypotheses remain highly speculative and should be investigated in deep.
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One limitation of this study was the absence of chitosan beads alone as control. The reason
is that it was not possible to prepare chitosan beads with embedded chondrocytes that were
suitable to culture. Indeed, chitosan solution must be prepared by chitosan powder dissolution
in acetic acid. Chondrocytes were then suspended in this acid solution that was no appropriate
with cells viability.
These results suggest that the CA beads could be used as cell carrier to repair traumatic or
degenerative cartilage lesion. Indeed, if implanted in cartilage lesion, chitosan-enriched bioma-
terial could promote cartilage matrix synthesis by chondrocytes but also decrease the local pro-
duction of inflammatory and catabolic factors. These multiple biological activities confer to
chitosan a benefit compared to other biomaterials. For example, a matrix composed with colla-
gen or with hyaluronic acid failed to decrease pro-inflammatory and pro-catabolic mediators
synthesis by chondrocytes [59, 60].
Conclusions
CA beads could be used as carrier for cell transplantation, particularly to repair degenerative
cartilage defect. This in vitro test highlighted beneficial and promising effects of this new bio-
material on human OA chondrocytes. They produced less inflammatory and catabolic media-
tors and maintained the synthesis of cartilage specific matrix components. All these biological
activities are beneficial for cartilage repair.
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